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ABSTRACT
Prostate cancer continues to be a major cause of morbidity and mortality in men, 
but a method for accurate prognosis in these patients is yet to be developed. The 
recent discovery of altered endosomal biogenesis in prostate cancer has identified 
a fundamental change in the cell biology of this cancer, which holds great promise 
for the identification of novel biomarkers that can predict disease outcomes. Here 
we have identified significantly altered expression of endosomal genes in prostate 
cancer compared to non-malignant tissue in mRNA microarrays and confirmed these 
findings by qRT-PCR on fresh-frozen tissue. Importantly, we identified endosomal 
gene expression patterns that were predictive of patient outcomes. Two endosomal 
tri-gene signatures were identified from a previously published microarray cohort 
and had a significant capacity to stratify patient outcomes. The expression of APPL1, 
RAB5A, EEA1, PDCD6IP, NOX4 and SORT1 were altered in malignant patient tissue, 
when compared to indolent and normal prostate tissue. These findings support 
the initiation of a case-control study using larger cohorts of prostate tissue, with 
documented patient outcomes, to determine if different combinations of these new 
biomarkers can accurately predict disease status and clinical progression in prostate 
cancer patients.
INTRODUCTION
Prostate cancer is the second most commonly 
diagnosed cancer in males [1], and the incidence of this 
disease is predicted to double globally by 2030 (WCRF 
prostate cancer statistics; http://globocan.iarc.fr, accessed 
May 2014). More than 1.1 million new cases of prostate 
cancer are diagnosed each year and two thirds of these 
patients are from the Western world. The marked increase 
in the age adjusted incidence rate for prostate cancer has 
been partly attributed to the prostate specific antigen 
(PSA) test identifying men without clinical symptoms 
of the disease. Unfortunately, the PSA biomarker neither 
discriminates between patients who are at a higher risk of 
progressive disease/mortality and those who have a more 
favorable prognosis, nor can it adequately distinguish 
between prostate cancer and benign pathologies [2, 3]. 
Therefore, there is a significant need for an effective 
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method to accurately define the prognosis for prostate 
cancer patients.
The investigation of biomarker expression by 
microarray analysis in patient cohorts, in relation to known 
clinical parameters, can be used to develop methods for 
determining patient prognosis [4-6]. Consequently, gene 
expression profiles that compare prostate cancer to benign 
prostatic hyperplasia (BPH), prostatic intraepithelial 
neoplasia (PIN) and normal prostate tissue have been 
generated from microarray data [4]. This approach has 
been utilized to identify the enzyme α-methylacyl-CoA 
racemase (AMACR), which was highly expressed in 
prostate cancer and may have value as a prognostic marker 
for the disease [7]. However, prostate cancers display 
substantial inter- and intra-tumor heterogeneity and the 
altered expression of a single gene may not be predictive 
for the wider prostate cancer cell population. In addition, 
altered gene expression may reflect de-differentiation and 
progression of tumor growth; for example, AMACR is an 
androgen-regulated gene and exhibits variable expression 
upon androgen-deprivation therapies or androgen-
independent disease progression [8]. Therefore, signatures 
incorporating multiple genes may be required to improve 
the accuracy of prostate cancer prognosis.
Commercial tests have recently been developed 
in an attempt to distinguish between aggressive prostate 
cancer and indolent disease (reviewed by Sartori & Chan 
2014 [9]). The Prolaris® test measures the expression of 
46 genes involved in cell cycle progression [10], whilst 
the Oncotype DX® Prostate Cancer Test measures the 
expression of genes involved in stromal response, cellular 
organization, proliferation, basal epithelial function, 
androgen signaling and stress response [11]. While these 
tests have entered clinical practice in the USA, and 
alongside the current PSA blood test, can be used to aid in 
clinical decision making, they do not predict progression to 
castrate-resistant cancer or determine responses of cancer 
cells to therapy [12]. Prostate cancer mRNA microarrays 
were used in the development of these biomarkers, 
suggesting that this approach has the potential to identify 
clinically-relevant new prostate cancer biomarkers. 
We recently reported that the biology of endosomes 
is markedly altered in prostate cancer cells [13, 14] 
and postulated that the expression of these genes might 
be predictive of disease progression in prostate cancer 
patients. Endosomes are essential organelles that are 
involved in cellular energy metabolism, cell division, 
intracellular signaling and degradation; and are known 
to have a role in cancer pathogenesis [15]. For example, 
endosomal cathepsins have previously been reported to 
be involved in the process of metastasis [16], presumably 
through their role in the degradation of extracellular 
matrix. The endosome system also has a specific capacity 
to respond to cellular and environmental change and may 
be altered as the cancer grows. We therefore hypothesized 
that endosome-related genes will be altered in prostate 
cancer and provide novel gene biomarkers for use in 
prostate cancer prognosis.
Here, we have investigated endosomal gene 
expression in multiple independent prostate cancer cohorts 
and developed two endosomal gene signatures that were 
predictive of patient outcome. We have also evaluated 
endosomal gene expression in fresh-frozen tissue sections 
from radical prostatectomies and demonstrated a capacity 
to distinguish indolent from aggressive tumors. This study 
provides evidence that endosomal genes can distinguish 
prostate cancer patient outcomes and predict disease 
progression, warranting further investigation of these 
findings in larger case-control studies.
RESULTS
Altered endosome associated gene expression in 
the Tomlins microarray patient cohort
The expression of APPL1 and EEA1 was 
significantly increased in primary prostate cancer when 
compared to non-malignant controls (P ≤ 0.05; Figure 
1). The expression of RAB5A and EEA1 was significantly 
reduced in metastatic prostate cancer when compared 
to primary prostate cancer tissue (P ≤ 0.05; Figure 1). 
The expression of RAB4A was significantly decreased 
in primary prostate cancer when compared to PIN tissue 
(P ≤ 0.05; Figure 1) and there was a significant reduction 
of RAB4A expression in metastatic prostate tissue when 
compared to both non-malignant prostate cancer (P ≤ 
0.01) and PIN tissue (P ≤ 0.0001; Figure 1). PDCD6IP 
was significantly decreased in metastatic prostate tissue 
when compared with both primary cancer and PIN tissue 
(P ≤ 0.01). The expression of NOX4 was significantly 
increased in metastatic prostate tissue when compared 
with PIN (P ≤ 0.05). Acid ceramidase (ASAH1) expression 
was significantly increased in PIN when compared to non-
malignant and primary prostate cancer tissue (P ≤ 0.05), 
and was significantly reduced in metastatic tissue when 
compared to primary prostate cancer (P ≤ 0.01), PIN (P ≤ 
0.0001), and non-malignant tissue (P ≤ 0.01). Cathepsin 
B (CTSB) expression was significantly reduced in both 
primary cancer tissue and metastatic cancer tissue when 
compared to non-malignant prostate tissue (P ≤ 0.01; 
Figure 1).
Endosome associated gene expression is associated 
with survival outcome in prostate cancer patients
From the Glinsky cohort [18], patients were 
classified into two groups of relative high and low mRNA 
expression of endosome-related genes with an arbitrary 
cut-point between the two groups defined by K-means 
clustering. There was increased expression of the cation-
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Figure 1: Vertical scatter plots of endosome-associated gene expression data from the Tomlins cohort [17]. Expression 
profiling data derived from the Chinnaiyan Human 20K Hs6 array of 18 non-malignant tissues, 13 prostatic intraepithelial neoplasias, 30 
primary prostate cancer and 19 metastatic cancer tissue samples were quantitated to show relative amount of expression of lysosomal-
related genes. Statistical significance is represented by an asterisk (*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001).
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independent mannose 6-phosphate receptor (IGF2R) in 
patients who had a greater risk of relapse (P = 0.007; 
Figure 2). Clustering of high or low cathepsin B (CTSB) 
expression revealed patients with lower CTSB expression 
had significantly increased risk of biochemical recurrence 
(P = 0.0306). There was also a significant stratification 
of patients with Sortilin (SORT1) expression, with those 
patients who expressed greater amounts of SORT1 at an 
increased risk of relapse (P = 0.004). Myosin 1B (MYO1B) 
stratified patients at risk of recurrence (P = 0.03), with 
patients having increased expression being associated with 
a poorer prognosis. There was a trend for lower expression 
of ALIX (PDCD6IP) to stratify patients with increased 
prostate cancer recurrence (P = 0.059), and reduced 
expression of Syntaxin 12 (STX12) was also indicative of 
at-risk patients, with significant stratification (P = 0.001; 
Figure 2).
Figure 2: Kaplan-Meier analysis of endosomal genes and patient stratification based on biochemical recurrence 
(BCR). Patients from the Glinsky cohort [18] were stratified into two groups by K-means clustering based on amount (high - black line, 
low - grey line) of gene expression in prostate cancer samples. Analysis was performed using the Log-Rank test. IGF2R (P = 0.007), CTSB 
(P = 0.03), MYO1B (P = 0.03), SORT1 (P = 0.004) and STX12 (P = 0.001) differentiated patients at risk of relapse based on the amount of 
gene expression showed evidence of prognostic capacity.
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Endosomal gene expression can predict clinical 
outcomes in prostate cancer patients with low 
amounts of PSA
Analysis from the Tomlins cohort suggested that the 
mRNA expression of endosome-related genes was altered 
during disease progression, and that they might therefore 
have prognostic capacity. Of the patients in the Glinsky 
cohort that had pre-prostatectomy PSA levels of less than 
10 ng/mL, 36.5% had biochemical failure at 100 months 
(data not shown). We postulated that the altered endosome 
gene expression in this patient group may indicate changes 
in cell biology that promote a more aggressive disease, 
and that this change could stratify patients at risk of 
recurrence, where the expression of PSA was low or 
borderline in blood samples.
Combinations of endosomal genes were analyzed 
to determine their potential for risk stratification, with a 
focus on genes related to functional endosome machinery 
in specific spatiotemporal compartments. Stratification 
of patients based on the expression of a RAB5A, APPL1 
and EEA1 tri-gene signature, using K-means clustering 
methodology, robustly separated patients into two groups 
with low or high expression of each of the three genes 
(Figure 3A). Kaplan-Meier survival analysis indicated 
that patients in the high expression group for this three-
gene signature were at significantly higher risk of 
biochemical recurrence when compared to those in the 
lower-expression group (HR 2.947, P = 0.0397, 95% CI 
1.069 - 9.259; Figure 3A). Importantly, stratification of 
patients based on the expression of a combined MYO1B, 
PDCD6IP and STX12 tri-gene signature, using K means 
clustering, robustly separated patients into a low- and 
high-risk group that showed a greater stratification 
capacity than any of the single genes (P = 0.003; HR 
2.947, P = 0.0397, 95% CI 1.069 - 9.259; Figure 3B). The 
high-risk group displayed lower expression of MYO1B and 
increased expression of both PDCD6IP and STX12.
qRT-PCR analysis of fresh-frozen prostate tissue 
revealed significantly altered endosome-associated 
gene expression in aggressive prostate cancer
qPCR analysis of endosome associated mRNA 
in fresh-frozen prostate cancer tissue demonstrated 
significantly increased expression of APPL1 in tissue 
from aggressive prostate cancer compared to non-
malignant prostate and indolent prostate cancer tissue (P 
≤ 0.01; Figure 4). The expression of RAB5A and EEA1 
were significantly increased in aggressive cancer tissue 
compared to indolent diseased tissue (P ≤ 0.05). The 
expression of NOX4 and SORT1 were also significantly 
increased in aggressive cancer tissue when compared with 
non-malignant (P ≤ 0.01) and indolent cancer tissue (P 
≤ 0.05). There was a significant reduction of PDCD6IP 
mRNA in indolent cancer tissue when compared to both 
non-malignant and aggressive prostate cancer tissue (P ≤ 
0.05 respectively).
Figure 3: A. Kaplan-Meier survival analysis of a combined APPL1, RAB5A and EEA1 gene signature for cancer patients expressing ≤ 
10 ng/mL PSA. Patients from the Glinsky cohort [18] expressing PSA ≤ 10 mg/mL were stratified into groups by K-means clustering based 
on RAB5A, APPL1 and EEA1 gene expression; the three-gene combined signature of APPL1, RAB5A and EEA1 stratified patients based on 
BCR (P ≤ 0.0397, Log-Rank test; high expression - black line, low expression - grey line). B. Kaplan-Meier survival analysis of MYO1B, 
PDCD6IP and STX12 expression and combined gene signature for cancer patients expressing ≤ 10 ng/mL PSA; the three-gene combined 
signature of MYO1B, PDCD6IP and STX12 stratified patients based on BCR (P ≤ 0.0029, Log-Rank test; low risk - black line, high risk - 
grey line). BCR: biochemical recurrence; HR: hazard ratio; CI: confidence interval.
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DISCUSSION
Prostate cancer is one of the most frequently 
diagnosed cancers in men, and a leading cause of cancer 
related deaths worldwide, particularly in the Western 
world [20, 21]. The PSA test is currently the gold-standard 
for prostate cancer detection, but is limited for specificity 
and has limited capacity for prognostic prediction [22]; 
consequently it cannot readily discriminate patients at 
higher risk of progressive disease or mortality from those 
who have a more favorable prognosis. Serum PSA results 
require contextual interpretation and judgment for each 
patient, however there are significant problems with 
specificity. The clinical decision-making process might be 
improved by the incorporation of multiple prostate cancer 
biomarkers, especially those that are associated with 
altered cancer cell biology.
Prognostic nomograms that incorporate continuous 
as well as categorical variables can potentially be 
improved by the integration of gene expression analysis 
and prognostic molecular signatures [23]. Our recent 
discovery of altered endosome biogenesis in prostate 
Figure 4: Vertical scatter plots of endosome-associated gene expression from qPCR mRNA analysis on non-malignant 
(n = 11), indolent (n = 5) and aggressive (n = 6) prostate cancer tissues from the Irish Prostate Cancer Research 
Consortium, Dublin, Ireland. Statistical significance is represented by an asterisk (*P ≤ 0.05; **P ≤ 0.01).
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cancer [14] suggests that the biologically relevant 
changes associated with these endosomal genes have the 
potential to improve the clinical decision-making process. 
There are an increasing number of commercial tests for 
biomarkers that complement the use of PSA (reviewed 
by Sartori & Chan 2014 [9, 24]), but these tests still do 
not adequately provide an early accurate prognosis for 
prostate cancer; and coincidentally, have been discovered 
anecdotally or through biomarker screening rather than 
by association with a cell biological process. Gene 
expression may also be altered throughout the course 
of the cancer growth and differentiation; for example, 
α methylacyl CoA racemase is an androgen-regulated 
gene and exhibits variable expression upon androgen-
deprivation therapies or androgen-independent disease 
progression [8], requiring continued monitoring of these 
changes. The combined ratio of PCA3 and PCA expression 
in prostate cells extracted from urine, can indicate the 
likelihood of prostate cancer, even if biopsies return 
a negative result [25]; providing a rationale for the use 
of multiple biomarkers. The altered gene expression in 
these adjunct tests can elucidate changes in the biology 
of prostate cancer, such as PCA3, which is associated 
with prostate cancer-cell survival and androgen receptor 
signaling [26]. This suggests that altered gene expression 
might need to be linked to functional cell biology to 
provide new avenues for the development of effective 
prognostic methodology. However, these new candidate 
genes can still be investigated in microarray cohorts to 
help retrospectively determine whether the biomarkers are 
informative of clinical outcome.
We recently reported that the biogenesis of 
endosomes is altered in prostate cancer, providing 
significant data on gene and protein expression in cultured 
prostate cells [13, 14]. We found that the molecular 
machinery involved in early endosome biogenesis had 
altered expression in prostate cancer cells, and that the 
intracellular location of these compartments was altered, 
leading to dysregulation of proliferative signals. To 
establish that these novel cellular changes were clinically 
relevant, we confirmed here that the endosomal mRNA 
expression was altered in prostate cancer tissues and was 
indicative of disease progression; suggesting that these 
biomarkers might be suitable for prognosis in prostate 
cancer patients. Our novel gene signatures stratified 
patients into high and low-risk disease recurrence groups 
and demonstrated prognostic potential in those patients 
expressing low or borderline amounts of PSA.
The genes employed for these prognostic 
signatures are associated with separate populations of 
early-endosome compartments, thus reflecting that the 
early endosome population as a whole is disturbed in 
prostate cancer, rather than one specific compartment, 
complementing the prior discovery of altered endosome 
biogenesis in prostate cancer [14]. Altered endosomal-
lysosomal biology and the associated changes in gene 
expression that occur during cancer development may 
be valuable prognostic indicators; for example, in breast 
cancer the increased expression of the endosomal protein 
acid ceramidase (ASAH1) has been associated with 
improved outcomes [27]. Interestingly, ASAH1 maps to 
chromosome 8p22, which is frequently deleted in prostate 
cancer patients [28, 29]. Endosomal CTSB (cathepsin B) is 
also found on chromosome 8p22 and the down regulation 
of CTSB in metastatic tissue may also relate to these 
chromosomal break points. The reductions in both ASAH1 
and CTSB expression in metastatic tissue may therefore 
be related to this deletion and furthermore is linked to the 
altered biogenesis of endosomes as these organelles are 
used to transport both of the latter enzymes.
The changes in APPL1 (3p21), RAB5A (3p24) and 
EEA1 (12q22) and RAB4A (1q42) in PIN or primary 
cancer tissue compared to their expression in non-
malignant tissue may discriminate metastatic tissue and 
provide an avenue for monitoring disease progression. 
The changes in the expression of endosomal genes 
observed in the Tomlins cohort suggested that they may 
be involved in the initiation or promotion of pre-malignant 
cell survival, and that sustained expression is not essential 
for the continued function of the malignant cell. Indeed, 
the transgenic adenocarcinoma of the mouse prostate 
(TRAMP) model of prostate cancer displays elevated gene 
expression in PIN tissue, which is later reduced in tumors 
[30]. The wide variation of gene expression changes in the 
metastatic tissue of the Tomlins cohort, when compared 
with primary cancer or PIN tissue may reflect the degree 
of dysfunction in these cells, which in turn contributed 
to the metastatic cascade. Further study with matched 
normal and disease samples would ascertain the extent of 
expression changes for each gene, for the development of 
a more refined method to predict disease progression.
Microarrays provide only a ‘snapshot’ of a cell 
population and there is potential for mRNA to be secreted 
prior to, or post protein-synthesis [31-33], complicating 
the interpretation of gene expression data. This regulation 
of the functional gene is equally critical to cancer cell 
biology and in the case of cathepsin B, the promotion of 
cancer metastasis through the hydrolytic activity of this 
enzyme [16]. Thus the incorporation of protein biomarkers 
and or functional enzymes, analyzed independently of 
their respective gene expression, may offer further insight 
into specific cell biology changes and provide more 
accurate prognosis.
We have noted the limitations of microarray gene 
expression analysis and consequently performed qPCR 
analysis of fresh-frozen prostate tissue to confirm our 
findings on endosomal gene expression. It should be 
recognized that the Glinsky cohort does not provide 
information on the gene expression in normal tissue 
from the cancer patients, or healthy individuals that have 
increased PSA independent of cancer occurrence, thus 
the current gene signatures are indicative of prognostic 
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potential rather than necessarily stratifying healthy 
individuals from those with prostate cancer. Furthermore, 
incorporating the Gleason scores from the Tomlins and 
Glinsky cohorts have been precluded from this study, due 
to the variability in the prognosis from this scoring system 
[34]. However, a dedicated case-control study utilizing 
these existing biomarkers and pathology tests, together 
with the endosomal biomarkers identified here, may result 
in an improved prognostic assay for prostate cancer.
The significant changes to APPL1, RAB5A and 
EEA1 gene expression in prostate tissue from aggressive 
disease compared to normal tissue or indolent-disease 
tissue indicates that these biomarkers have significant 
potential to monitor disease progression and to stratifying 
patients at risk of progressive and or metastatic disease. 
They also have important biological relevance that could 
provide a therapeutic target, since alterations in endosome 
biogenesis can result in significantly altered intracellular 
cell signaling, result in increased cell proliferation and 
in combination with NOX4 the expression promote 
inflammation and angiogenesis [35].
In summary, endosomal gene expression and 
specific gene signatures have the potential to prediction 
disease progression in prostate cancer patients and this 
may lead to improved treatment outcomes. Multivariate 
risk analysis and stratification of patients into low- and 
high-risk groups may provide a more individualized 
approach to prostate cancer patient management, reducing 
the amount of over-treatment [36]. Active-surveillance is 
often used for patients deemed to have low-risk prostate 
cancer (e.g. clinical category T1c, Gleason score ≤ 6, 
and PSA ≤ 10 ng/mL), but older men are at an increased 
risk of mortality from prostate cancer, despite low 
pathology scores and low PSA serum concentrations 
[37]. Examination of the survival rates for prostate cancer 
patients expressing low PSA, which is typical of an active 
surveillance group, reveals some prostate cancers that are 
aggressive and that result in more rapid recurrence. In 
the current study, quantitation of gene signatures for the 
early endosomal genes APPL1, EEA1 and RAB5A, and 
analysis of the endosomal genes MYO1B, PDCD6IP and 
STX12 in prostate cancer patients expressing PSA ≤ 10 
ng/mL, led to patient stratification into high and low-risk 
recurrence groups. These findings justify further clinical 
investigation of these biomarkers and gene signatures in 
a dedicated case-control study. Recognizing that prostate 
cancer patients have altered endosomal gene expression 
is a significant step towards the development of new, 
biology-driven biomarkers that could provide accurate 
prognosis for this important disease.
MATERIALS AND METHODS
Patient cohorts
The Tomlins [17] cohort was chosen for its curation 
of multiple disease stages of prostate cancer. Analysis of 
tissue samples from this cohort was previously performed 
using the Chinnaiyan Human 20K Hs6 array [17] and was 
retrieved from NCBI GEO (accession number GSE6099). 
It is comprised of 18 non-malignant tissues, 13 prostatic 
intraepithelial neoplasia’s (PIN), 30 primary prostate 
cancers obtained from radical prostatectomies and 19 
metastatic cancer tissue samples were obtained from 
hormone refractory metastases in the liver, lung or lymph 
tissue [17]. The Glinsky cohort [18] was obtained from 
patients who had been treated by radical prostatectomy 
at Memorial Sloan-Kettering Cancer Center (MSKCC) 
and was composed of 79 malignant prostate tissues, 
with clinical follow-up data over 8 years, which was 
used to assess prostate cancer biochemical recurrence. 
This cohort comprised 29 patients with biochemical 
recurrence as defined by a PSA concentration ≥ 0.2 ng/
mL and 50 patients with no disease progression. Samples 
in this cohort had been examined histologically using 
H&E-stained cryostat sections, non-neoplastic tissues 
removed from tumor samples and cells of interest 
manually dissected from the frozen block, with other 
tissues trimmed away [18]. Fresh-frozen prostate samples 
were provided by the Irish Prostate Cancer Research 
Consortium (PCRC) Bioresource, Conway Institute 
of Biomolecular and Biomedical Research, University 
College Dublin, Ireland; following approval from the 
Mater Misericordiae University Hospital ethics committee 
and written informed consent from all patients. The 
curated samples were selected based on the disease status 
of “aggressive” or “indolent”. Aggressive disease samples 
(n = 6) were selected from patients with biochemical 
recurrence (Median 27 months) and the median Gleason 
score was 7 with evidence of capsular invasion. Indolent 
cancer samples (n = 5) were selected from patients with no 
biochemical recurrence and had a median Gleason score 
of 5, with no evidence of capsular invasion. Matched 
non-malignant tissues (n = 11) were also obtained from 
this cohort. Tissue histology was further confirmed by an 
expert pathologist upon re-section of each tissue specimen 
and subsequent H&E staining. Based on the histology 
findings, a portion of prostate tissue, containing the 
highest tumor content, was cut from the specimen. These 
sub-samples were stored at -80 oC before RNA extraction.
Quantitative RT-PCR
Quantitative RT-PCR was performed on patient 
samples from the Irish PCRC cohort. RNA was extracted 
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from non-malignant (n = 11), indolent (n = 5) and 
aggressive cancer tissues (n = 6). Reverse transcription of 
500 ng of total RNA was performed using a high-capacity 
cDNA Reverse Transcription Kit (Life Technologies Pty. 
Ltd., Cat# 4368814). Real-time PCR was performed 
using 2 μL cDNA for each of the following TaqMan® gene 
expression assays (Single Tube TaqMan® Gene Expression 
Assays Life Technologies); APPL1 (Hs00179382_m1), 
RAB5A (Hs00991290_m1), EEA1 (Hs00929215_m1), 
PDCD6IP (Hs00994346_m1), NOX4 (Hs00418356_m1), 
SORT1 (Hs00361760_m1) and TaqMan® Gene Expression 
Master Mix in a total volume of 10 μL. Three biological 
replicates were performed consisting of three technical 
replicates. Expression of each gene was normalized to 
an average of ALAS1 (Hs00963534_m1) and HPRT1 
(Hs02800695_m1) reference genes and relative quantities 
calculated by ΔCt.
Statistical analysis
A Kruskal-Wallis test with Dunn’s multiple 
comparison was performed to evaluate differences in 
gene expression between multiple groups in the Tomlins 
cohort. Data from the Glinsky cohort was analyzed using 
K-means clustering by Cluster 3.0 [19] to determine 
high and low gene expression groups. These groups 
were evaluated using Kaplan-Meier survival curves with 
differences determined using the Log-Rank (Mantel-Cox) 
test. The construction of tri-gene signatures also used 
K-means clustering methodology to cluster the expression 
values of the three genes from each tissue, resulting in 
two clusters representing high or low expression for each 
of the three genes. One-way ANOVA was performed to 
evaluate expression differences between non-malignant, 
indolent and aggressive prostate cancer tissues from the 
PCRC bioresource. All statistical tests were performed 
using GraphPad Prism 6.05 (GraphPad Software Inc., 
California, USA). Significant results showed greater than 
95% confidence (P < 0.05).
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